Ginkgo Bioworks Holdings, Inc.
DNA
$9.03
-$0.52-5.45%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 180.61M | 230.82M | 237.42M | 227.04M | 217.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 180.61M | 230.82M | 237.42M | 227.04M | 217.95M |
| Cost of Revenue | 49.29M | 48.49M | 47.39M | 44.55M | 41.54M |
| Gross Profit | 131.31M | 182.32M | 190.02M | 182.50M | 176.41M |
| SG&A Expenses | 189.26M | 196.60M | 219.61M | 240.85M | 253.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 508.58M | 522.77M | 625.53M | 709.46M | 760.20M |
| Operating Income | -327.97M | -291.95M | -388.11M | -482.42M | -542.25M |
| Income Before Tax | -340.07M | -316.09M | -472.50M | -547.51M | -651.54M |
| Income Tax Expenses | -519.00K | -895.00K | -422.00K | -479.00K | -352.00K |
| Earnings from Continuing Operations | -339.55 | -315.19 | -472.08 | -547.03 | -651.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -339.55M | -315.19M | -472.08M | -547.03M | -651.19M |
| EBIT | -327.97M | -291.95M | -388.11M | -482.42M | -542.25M |
| EBITDA | -280.99M | -241.27M | -335.89M | -432.70M | -495.35M |
| EPS Basic | -6.23 | -5.85 | -8.98 | -10.62 | -12.90 |
| Normalized Basic EPS | -3.52 | -3.06 | -4.19 | -5.28 | -5.99 |
| EPS Diluted | -6.23 | -5.86 | -8.99 | -10.63 | -12.92 |
| Normalized Diluted EPS | -3.52 | -3.06 | -4.19 | -5.28 | -5.99 |
| Average Basic Shares Outstanding | 218.55M | 215.16M | 211.67M | 207.54M | 203.16M |
| Average Diluted Shares Outstanding | 218.55M | 215.16M | 211.68M | 207.57M | 203.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |